Talis Biomedical Corporation IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Talis Biomedical Corporation | TLIS - NASDAQ |
$14.00-$16.00 | $16.00 | $29.00 | 13.8 million | 2/12/2021 |
| JP Morgan, BofA Securities, Piper Sandler | ||||||
Co-Manager(s): BTIG | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-01-22 Terms Added 2021-02-08 Amended Terms 2021-02-11 | ||||||
Talis Biomedical Corporation Quote & Chart - Click for current quote - TLIS
IPO Boutique aggregates information on public companies and private companies, such as "TLIS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Talis Biomedical Corporation (adapted from Talis Biomedical Corporation prospectus):
Talis aims to transform diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases and other conditions at the point-of-care.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
Talis aims to transform diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases and other conditions at the point-of-care.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "TLIS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.